XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended
Apr. 30, 2006
Jun. 30, 2005
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue     $ 55,902,000 $ 36,161,000  
Deferred Revenue     12,863,000   $ 12,740,000
Drug Product Revenue, Net [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue     24,486,000 2,109,000  
Japan [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Transaction price, variable consideration from estimated future co-development billing     $ 0    
Japan [Member] | Drug Product Revenue, Net [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Total revenue       $ 1,700,000  
Astellas Agreement [Member] | Japan [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Upfront, non-contingent and time-based payments received   $ 172,600,000      
Additional consideration based on net sales description     the low 20% range of the list price    
Aggregate consideration received excluding drug product revenue     $ 105,100,000    
Changes in revenue from changes to estimated variable consideration     $ 0    
Astellas Agreement [Member] | Europe [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Upfront, non-contingent and time-based payments received $ 745,000,000        
Additional consideration based on net sales description     low 20% range    
Aggregate consideration received excluding drug product revenue     $ 685,000,000    
Percentage of joint development costs committed to fund 50.00%        
Changes in revenue from changes to estimated variable consideration     $ 0